IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.3553
+0.0100 (2.90%)
At close: Aug 13, 2025, 4:00 PM
0.3555
+0.0002 (0.06%)
Pre-market: Aug 14, 2025, 8:19 AM EDT
IGC Pharma Revenue
In the fiscal year ending March 31, 2025, IGC Pharma had annual revenue of $1.27M, down -5.50%. IGC Pharma had revenue of $330.00K in the quarter ending March 31, 2025, with 11.86% growth.
Revenue (ttm)
$1.27M
Revenue Growth
-5.50%
P/S Ratio
21.39
Revenue / Employee
$18,157
Employees
70
Market Cap
29.81M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 1.27M | -74.00K | -5.50% |
Mar 31, 2024 | 1.35M | 434.00K | 47.64% |
Mar 31, 2023 | 911.00K | 514.00K | 129.47% |
Mar 31, 2022 | 397.00K | -501.00K | -55.79% |
Mar 31, 2021 | 898.00K | -3.17M | -77.95% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
IGC News
- 1 day ago - IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1 - Accesswire
- 8 days ago - IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression - Accesswire
- 21 days ago - IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025 - Accesswire
- 23 days ago - IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards - Accesswire
- 4 weeks ago - IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection - Accesswire
- 6 weeks ago - IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation - Accesswire
- 6 weeks ago - IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025 - Accesswire
- 7 weeks ago - IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon - Accesswire